Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Total Current Liabilities (2019 - 2025)

Revolution Medicines has reported Total Current Liabilities over the past 7 years, most recently at $290.4 million for Q4 2025.

  • Quarterly results put Total Current Liabilities at $290.4 million for Q4 2025, up 77.18% from a year ago — trailing twelve months through Dec 2025 was $290.4 million (up 77.18% YoY), and the annual figure for FY2025 was $290.4 million, up 77.18%.
  • Total Current Liabilities for Q4 2025 was $290.4 million at Revolution Medicines, up from $245.6 million in the prior quarter.
  • Over the last five years, Total Current Liabilities for RVMD hit a ceiling of $290.4 million in Q4 2025 and a floor of $43.8 million in Q1 2021.
  • Median Total Current Liabilities over the past 5 years was $81.8 million (2023), compared with a mean of $108.7 million.
  • Peak annual rise in Total Current Liabilities hit 132.08% in 2023, while the deepest fall reached 4.91% in 2023.
  • Revolution Medicines' Total Current Liabilities stood at $60.4 million in 2021, then increased by 2.71% to $62.0 million in 2022, then skyrocketed by 132.08% to $143.9 million in 2023, then rose by 13.95% to $163.9 million in 2024, then surged by 77.18% to $290.4 million in 2025.
  • The last three reported values for Total Current Liabilities were $290.4 million (Q4 2025), $245.6 million (Q3 2025), and $184.5 million (Q2 2025) per Business Quant data.